C.R. Bard downgraded to Sell from Underperform at CLSA CLSA downgraded CR Bard based on concerns its risk profile has increased with its new multi-year-plan following disappointing guidance. Price target lowered to $96 from $98.
News For BCR From The Last 14 Days
Check below for free stories on BCR the last two weeks.